Supervisory boardHans Schikan, PharmD, chairman Former CEO of Prosensa. Mark Vaeck, PhD CEO of Complix, and former CEO of ActoGeniX and Ablynx. Brian Bronk, PhD Head of External Innovation for Rare Diseases at Sanofi. Karl Rothweiler, MBA Aglaia Biomedical Ventures. Samuel Gerssen, MSc, MBA Waterman 40 Holding. Pieter Rhemrev, MSc. Oost NL.